Liprolog

Withdrawn

This medicine's authorisation has been withdrawn

insulin lispro

Overview

The marketing authorisation for Liprolog has been withdrawn at the request of the marketing authorisation holder.

Product information

19/02/2001

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

• summary of product characteristics (annex I);
• manufacturing authorisation holder responsible for batch release (annex IIA);
• conditions of the marketing authorisation (annex IIB);
• labelling (annex IIIA);
• package leaflet (annex IIIB).

Product details

• Name of medicine:
  Liprolog
• Active substance:
  insulin lispro
• International non-proprietary name (INN) or common name:
  insulin lispro
• Therapeutic area (MeSH):
  Diabetes Mellitus
• Anatomical therapeutic chemical (ATC) code:
  A10AB04

Pharmacotherapeutic group

• Drugs used in diabetes
• Insulins and analogues for injection, fast-acting

Therapeutic indication

For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilization of diabetes mellitus. Liprolog is a short acting insulin and may be used in conjunction with a longer acting human insulin. Liprolog is indicated for preprandial administration.

Authorisation details

• EMA product number:
  EMEA/H/C/000143
• Marketing authorisation holder:
  Eli Lilly and Company Limited

  Kingsclere Road; Basingstoke; Hants RG21 6XA; United Kingdom

• Marketing authorisation issued:
  07/05/1997